Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
University of Wisconsin, Madison
Study ID
NCT07125209
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Patient Reported Outcomes Assessment — OTHER
    Functional Assessment of Cancer Therapy - Ovarian (FACT-O) and Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) will be used to assess patient reported outcomes.
  • Cognitive and General Health Assessments — OTHER
    * Rey Verbal Learning Test * Trail Making Test * Patient Health Questionnaire (PHQ-2) * Mini Mental State Exam (MMSE) * Controlled Oral Word Association Test of the Multilingual Aphasia Examination

Study Details

The purpose of this research is to assess several components of cognition in patients recently diagnosed with advanced epithelial ovarian cancer and who will be undergoing neoadjuvant chemotherapy for treatment of the cancer. 18 participants will be enrolled and can expect to be on study for approximately 10 months.

Key Dates

Start date
Apr 28, 2026
Status verified
Apr 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
18 participants (estimated)

Arms

  • Arm: Receiving Neoadjuvant Chemotherapy for Ovarian Cancer

Primary Outcome Measure

The Mini Mental State Exam (MMSE) [ Time Frame: baseline, after 3 cycles of neoadjuvant chemotherapy (up to 2 months), after completion of adjuvant therapy (up to 4 months), and 6 months following treatment (up to 10 months on study) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UW Carbone Cancer CenterMadisonWisconsin53792-

Find similar trials in Madison, WI

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
UW Carbone Cancer Center· Madison, WI

Related Studies